Cite
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
MLA
Ocio, E. M., et al. “In Vivo Murine Model of Acquired Resistance in Myeloma Reveals Differential Mechanisms for Lenalidomide and Pomalidomide in Combination with Dexamethasone.” Leukemia (08876924), vol. 29, no. 3, Mar. 2015, pp. 705–14. EBSCOhost, https://doi.org/10.1038/leu.2014.238.
APA
Ocio, E. M., Fernández-Lázaro, D., San-Segundo, L., López-Corral, L., Corchete, L. A., Gutiérrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., Montero, J. C., Díaz-Rodríguez, E., Mateos, M. V., Pandiella, A., Couto, S., Wang, M., Bjorklund, C. C., & San-Miguel, J. F. (2015). In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia (08876924), 29(3), 705–714. https://doi.org/10.1038/leu.2014.238
Chicago
Ocio, E M, D Fernández-Lázaro, L San-Segundo, L López-Corral, L A Corchete, N C Gutiérrez, M Garayoa, et al. 2015. “In Vivo Murine Model of Acquired Resistance in Myeloma Reveals Differential Mechanisms for Lenalidomide and Pomalidomide in Combination with Dexamethasone.” Leukemia (08876924) 29 (3): 705–14. doi:10.1038/leu.2014.238.